Quintessence Biosciences, Inc.

Who is Quintessence Biosciences?

What is the EVade™ Ribonuclease Technology?

How was the EVade™ Ribonuclease Technology Discovered?

Quintessence Biosciences, Inc.
505 South Rosa Road
Madison, Wisconsin 53719 USA
Phone: +1-608.441.2950
Fax: +1-608.441.2952

Management

Business Board

Science Board

Careers

Science Board

The members of the Scientific Advisory Board are Dr. Howard H. Bailey, Dr. Laura L. Kiessling, Dr. Ronald T. Raines, Dr. Paul M. Sondel and Dr. Laura E. Strong.

Howard H. Bailey, M.D.

Dr. Bailey graduated from the University of North Dakota Medical School and received his Internal Medicine training at Kalamazoo, Michigan. He performed fellowship training in Medical Oncology at the University of Wisconsin as well as a Research Fellowship at the University of Wisconsin Comphrehensive Cancer Center. He has been a faculty member of the University of Wisconsin Medical School since 1994. He currently is an Assistant Professor of Medicine in the section of Medical Oncology. Dr. Bailey's clinical expertise and research is focused on the medical treatment of adult malignancies with a special focus on the following: gynecologic malignancies, use of investigational anti-cancer agents, and sarcomas.

Dr. Laura L. Kiessling, Founder

Laura L. Kiessling, Ph.D., also a founder of the company, is a leading expert on multivalency as well as the chemistry and biology of carbohydrates and nucleic acids. Dr. Kiessling serves on the Company's Board of Directors and on the Scientific Advisory Board. As inventor of a number of the technologies licensed exclusively to the Company, Dr. Kiessling continues to provide guidance on the development and commercialization of those technologies. Dr. Kiessling received a Ph.D. degree in Organic Chemistry from Yale University and did postdoctoral work in Chemistry at the California Institute of Technology. In 1991, she joined the faculty at the University of Wisconsin--Madison, where she is now Professor of Chemistry and Biochemistry. Dr. Kiessling has served as a Scientific Advisory Board member or consultant for numerous pharmaceutical and biotechnology companies. She is on the Editorial Boards of Chemistry & Biology, Carbohydrate Research, and Organic Reactions. Dr. Kiessling has won national awards for her research, including a 1999 MacArthur Fellowship for the discovery of the Neobiopolymer(TM) technology and an Arthur C. Cope Scholar Award in Organic Chemistry from the American Chemical Society. She has been cited as one of "50 R&D Stars to Watch" (Industry Week; December 6, 1999).

Dr. Ronald T. Raines, Founder

Ronald T. Raines, Ph.D., a founder of the Company, is a leading expert on the chemistry and biology of proteins. Dr. Raines serves on the Company's Board of Directors and is a senior member of the Scientific Advisory Board. In these positions, he provides oversight on the scientific direction of the company. As inventor of a number of the technologies licensed exclusively to Quintessence Biosciences, Dr. Raines provides guidance on the development and commercialization of these technologies. Dr. Raines received A.M. and Ph.D. degrees in organic chemistry from Harvard University and did postdoctoral research in biochemistry and biophysics at the University of California, San Francisco. In 1989, he joined the faculty at the University of Wisconsin–Madison, where he is now the Henry Lardy Professor of Biochemistry and a Professor of Chemistry. Dr. Raines has served as a Scientific Advisory Board member or consultant for numerous pharmaceutical and biotechnology companies and has been a Visiting Scientist at Chiron Corporation. He is on the Editorial Boards of ACS Chemical Biology and Peptide Science. Dr. Raines is an author of over 200 scientific articles and has won national and international awards for his research, including the 1998 Pfizer Award in Enzyme Chemistry and 2004 Arthur C. Cope Scholar Award from the American Chemical Society, the 2005 Emil Thomas Kaiser Award from the Protein Society, and a 2001–2002 Guggenheim Fellowship. He is a fellow of the American Association for the Advancement of Science and the Royal Society of Chemistry. Dr. Raines is the inventor of the S-TAG™ technology, which has been licensed by Novagen, Inc.

Paul M. Sondel, M.D., Ph.D.

Dr. Sondel received a Ph.D. in genetics at the University of Wisconsin-Madison. He graduated from Harvard Medical School and did an internship at the University of Minnesota Hospital. Dr. Sondel then did his residency in the Department of Pediatrics at the University of Wisconsin-Madison. He has been a faculty member of the University of Wisconsin Medical School since 1980. He currently is a Professor in the Departments of Pediatrics and Human Oncology at UW Medical School and Program Leader for Immunology and Immunotherapy at the University of Wisconsin Comprehensive Cancer Center. He has co-authored over 300 publications. Dr. Sondel's does research related to immune modulation as treatment for malignancy.